AMBS — Amarantus Bioscience Holdings Share Price
Last trade - 00:00- $0.06m
- $38.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 0 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.
Directors
- Gerald Commissiong PRE (33)
- Barney Monte CFO
- John Commissiong CSO (71)
- Marc Faerber VOP (61)
- Conn Flanigan DRC (50)
- Steven Spence DRC
- Robert Harris IND (72)
- Donald Huffman IND (69)
- Last Annual
- December 31st, 2018
- Last Interim
- March 31st, 2016
- Incorporated
- March 22nd, 2013
- Public Since
- September 29th, 2008
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 630,607,411
- Address
- 655 Montgomery Street, Suite 900, SAN FRANCISCO, 94111
- Web
- https://www.amarantus.com/
- Phone
- +1 4087372734
- Auditors
- Marcum LLP
Upcoming Events for AMBS
Similar to AMBS
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 19:13 UTC, shares in Amarantus Bioscience Holdings are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Amarantus Bioscience Holdings last closed at $0.00 and the price had moved by -80% over the past 365 days. In terms of relative price strength the Amarantus Bioscience Holdings share price has underperformed the S&P500 Index by -84.39% over the past year.
There is no consensus recommendation for this security.
Find out moreAmarantus Bioscience Holdings does not currently pay a dividend.
Amarantus Bioscience Holdings does not currently pay a dividend.
Amarantus Bioscience Holdings does not currently pay a dividend.
To buy shares in Amarantus Bioscience Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Amarantus Bioscience Holdings had a market capitalisation of $0.06m.
Here are the trading details for Amarantus Bioscience Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AMBS
Based on an overall assessment of its quality, value and momentum Amarantus Bioscience Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amarantus Bioscience Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -10.28%.
As of the last closing price of $0.00, shares in Amarantus Bioscience Holdings were trading -85.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Amarantus Bioscience Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Amarantus Bioscience Holdings' management team is headed by:
- Gerald Commissiong - PRE
- Barney Monte - CFO
- John Commissiong - CSO
- Marc Faerber - VOP
- Conn Flanigan - DRC
- Steven Spence - DRC
- Robert Harris - IND
- Donald Huffman - IND